Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma. Current opinion in supportive and palliative care [Curr Opin Support Palliat Care] Journal article | | Title | Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma. | | Author(s) | Guevremont C, Alasker A, Karakiewicz PI | | Institution | aCancer Prognostics and Health Outcomes Unit, University of Montreal, Canada bDepartment of Urology, University of Montreal Health Center (CHUM), Montreal, Canada. | | Source | Curr Opin Support Palliat Care 2009 Jun 12. | | Abstract | PURPOSE OF REVIEW: To review the common and serious toxicities associated with the use of tyrosine kinase inhibitors such as sorafenib and sunitinib and mTOR inhibitor temsirolimus, and to outline the most recent toxicity management guidelines.
RECENT FINDINGS: Common grade 3 or 4 side effects with sorafenib include lymphopenia (13%), hypophosphatemia (13%), elevated lipase (12%), hand-foot syndrome (6%), and mucositis/stomatitis (6%). Common grade 3 or 4 side effects with suntinib elevated lipase (16%), neutropenia (12%), lymphopenia (12%), hypertension (8%), and fatigue/asthenia (7%). As for temsirolimus, common grade 3 or 4 side effects consist of anemia (20%), hyperglycemia (11%), fatigue/asthenia (11%), dyspnea (9%), and hypophosphatemia (5%). Intracranial hemorrhage (ICH) is rare but occurred in sorafenib-exposed and sunitinb-exposed patients. Cardiovascular morbidity may also be observed in sorafenib-exposed and sunitinib-exposed patients.
SUMMARY: Through preventive and therapeutic measures, these side effects can be effectively managed, without reducing the dose and, therefore, affecting the efficacy of the treatment. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19528803 |
|
|
| |
Advertise on this site.
| | |
|
